Michael J. McElhaugh
Net Worth
Last updated:
What is Michael J. McElhaugh net worth?
The estimated net worth of Mr. Michael J. McElhaugh is at least $8,892,697 as of 2 Feb 2024. He owns shares worth $5,251,728 as insider, has earned $623,869 from insider trading and has received compensation worth at least $3,017,100 in Arbutus Biopharma Corporation.
What is the salary of Michael J. McElhaugh?
Mr. Michael J. McElhaugh salary is $603,420 per year as Chief Bus. Officer in Arbutus Biopharma Corporation.
How old is Michael J. McElhaugh?
Mr. Michael J. McElhaugh is 51 years old, born in 1974.
What stocks does Michael J. McElhaugh currently own?
As insider, Mr. Michael J. McElhaugh owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Arbutus Biopharma Corporation (ABUS) | Chief Bus. Officer | 1,504,793 | $3.49 | $5,251,728 |
What does Arbutus Biopharma Corporation do?
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Michael J. McElhaugh insider trading
Arbutus Biopharma Corporation
Mr. Michael J. McElhaugh has made 5 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 10,164 units of ABUS stock worth $23,509 on 2 Feb 2024.
The largest trade he's ever made was exercising 40,000 units of ABUS stock on 14 Dec 2020. As of 2 Feb 2024 he still owns at least 1,504,793 units of ABUS stock.
Arbutus Biopharma key executives
Arbutus Biopharma Corporation executives and other stock owners filed with the SEC:
- Dr. Michael J. Sofia Ph.D. (67) Chief Scientific Officer
- Mr. Michael J. McElhaugh (51) Chief Bus. Officer
- Mr. William H. Collier (65) Pres, Chief Executive Officer & Director